| |
Phase 2 Efficacy and Safety of the Novel Viral Entry Inhibitor, TNX-355, in Combination with Optimized Background Regimen (OBR)
|
| |
| |
Reported by Jules Levin
XVI Intl AIDS Conference, Toronto, Aug 17, 2006
D. NORRIS1, J. MORALES2, J. GATHE3, E. GODOFSKY4, F. GARCIA5, R. HARDWICKE6, S. LEWIS7
Comprehensive Research Center, Tampa, FL1, Clinical Research Puerto Rico Inc., San Juan, PR2, Therapeutic Concepts, Houston, TX3, Bach & Godofsky, Bradenton, FL4; Valley AIDS Council, Harlingen, TX5, University of Texas Health Science Center,
Houston, TX6, Tanox, Inc., Houston, TX7
|
|
| |
| |
|
|
|
